Arterial Destiffening With Atorvastatin in Overweight and Obese Middle-Aged and Older Adults

Abstract

Abstract-We hypothesized that atorvastatin (ATOR) treatment would reduce arterial stiffness in overweight and obese middle-aged and older adults. Twenty-six (11 men and 15 women) overweight or obese (body mass index: 31.6Ϯ0.7 kg/m 2 ) middle-aged and older adults (age: 54Ϯ2 years) were randomly assigned to receive either ATOR (80 mg/d) or placebo for 12 weeks. Arterial stiffness (␤-stiffness and pulse wave velocity) was measured before and after the intervention. At baseline, the ATOR (nϭ16) and placebo (nϭ10) groups did not differ with respect to age, body mass index, blood pressure, serum lipid and lipoprotein concentrations, high-sensitivity C-reactive protein, indices of arterial stiffness, or compliance (all PϾ0.05). After the 12-week treatment period, the ATOR group experienced a 47% reduction in low-density lipoprotein cholesterol (149Ϯ6 to 80Ϯ8 mg/dL) and a 42% reduction in high-sensitivity C-reactive protein (3.6Ϯ0.8 to 2.1Ϯ0.5 mg/L; both PϽ0.05). In addition, ␤-stiffness (9.4Ϯ0.6 to 7.6Ϯ0.5 U) and aortic pulse wave velocity (1096Ϯ36 to 932Ϯ32 cm/s), but not brachial pulse wave velocity, decreased (both PϽ0.05) with ATOR. In contrast, there were no significant changes in ␤-stiffness (9.1Ϯ0.8 to 9.1Ϯ0.7 U) or aortic pulse wave velocity (1238Ϯ89 to 1191Ϯ90 cm/s; both PϾ0.05) in the placebo group. There were no relations between the reductions in arterial stiffness indices and any of the baseline cardiometabolic risk factors (all PϾ0.05). However, the reductions in arterial stiffness were correlated with the reduction in low-density lipoprotein cholesterol but not high-sensitivity C-reactive protein or any other cardiometabolic variables (all PϽ0.05). Taken together, these findings suggest that ATOR reduces arterial stiffness in overweight and obese middle-aged and older adults, and these favorable changes occur irrespective of baseline cardiometabolic risk factors.

Singular and combined effects of nebivolol and lifestyle modification on large artery stiffness in hypertensive adults

“…18-40 years) individuals previously studied in our laboratory [Orr et al 2009]. As such, there would appear to be significant 'residual risk' which remains following the treatment period in each of 4.1 ± 1.2 4.0 ± 1.5 4.8 ± 0.9 6.6 ± 1.7 5.4 ± 1.5 6.6 ± 2.1 IL-6, pg/dL 14.7 ± 0.4 13.9 ± 0.7 15.0 ± 0.7 20.1 ± 5.6 15.7 ± 1.2 15.2 ± 1.4 TNF-α, pg/dL 9.2 ± 0.4 8.9 ± 0.3 12.9 ± 3.7 11.3 ± 1.4 13.0 ± 3.7 11.4 ± 1.4…”

Pulse Pressure and Target Organ Damage

“…In contrast, in clinical trials, atenolol or pure beta-blockade based-therapy did not provide cardiovascular protection compared to that afforded by newer classes of BP lowering agent, Administration of statins to overweight and obese subjects was associated with an improvement in arterial stiffness as evidenced by a significant reduction in PWV, independent of baseline cardiometabolic risk factors (Orr et al, 2009). …”

Atorvastatin — 20 Years in the Struggle for Life

“…пациентам с ожирением в течение 12 нед. привело к сни-жению СПВ в аорте с 1099 см/сек до 932 см/сек, р<0,05 [34]. Wang J, et al оценили влияние терапии аторвастатином в течение 6 мес.…”